These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28654314)

  • 1. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
    Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
    J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
    Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
    J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
    Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
    J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating an Exercise Detection, Grading, and Hormone Dosing Algorithm Into the Artificial Pancreas Using Accelerometry and Heart Rate.
    Jacobs PG; Resalat N; El Youssef J; Reddy R; Branigan D; Preiser N; Condon J; Castle J
    J Diabetes Sci Technol; 2015 Oct; 9(6):1175-84. PubMed ID: 26438720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Model Predictive Control of Bihormonal Artificial Pancreas System Based on Switching Control and Dynamic R-parameter.
    Tang F; Wang Y
    J Diabetes Sci Technol; 2017 Nov; 11(6):1112-1123. PubMed ID: 28728434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.
    Pontiroli AE; Tagliabue E
    Acta Diabetol; 2020 Jun; 57(6):743-749. PubMed ID: 32025860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
    Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
    J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
    Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evaluation of Glucagon Injection Anxiety and Its Association with the Fear of Hypoglycemia among the Parents of Children with Type 1 Diabetes.
    Muradoğlu S; Yeşiltepe Mutlu G; Gökçe T; Can E; Hatun Ş
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):285-292. PubMed ID: 33491925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining basal-bolus insulin infusion for tight postprandial glucose control: an in silico evaluation in adults, children, and adolescents.
    Revert A; Rossetti P; Calm R; Vehí J; Bondia J
    J Diabetes Sci Technol; 2010 Nov; 4(6):1424-37. PubMed ID: 21129338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.
    Lv D; Breton MD; Farhy LS
    Diabetes Technol Ther; 2013 Nov; 15(11):935-41. PubMed ID: 23978267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.
    Clarke WL; Anderson S; Breton M; Patek S; Kashmer L; Kovatchev B
    J Diabetes Sci Technol; 2009 Sep; 3(5):1031-8. PubMed ID: 20144416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.